BlackRock Fund Advisors’s Viridian Therapeutics VRDN Stock Holding History

BlackRock Fund Advisors’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$1K	Buy	8 +1	+14%	+$104	﹤0.01%	4202
2016 Q3	$1K	Buy	7 +1	+17%	+$112	﹤0.01%	4230
2016 Q2	$1K	Buy	+6	New	+$736	﹤0.01%	4290

Other funds holding VRDN

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCM

Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BlackRock Fund Advisors's VRDN Position: Q4 2016 in Review

BlackRock Fund Advisors increased its Viridian Therapeutics (VRDN) stake by 14% in Q4 2016, buying an estimated $104 and bringing the position to 8 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #4202.

BlackRock Fund Advisors first reported a position in VRDN in Q2 2016 and has held it in 3 quarters since. 8 funds tracked by Wall St. Rank hold VRDN as of Q4 2016.

BlackRock Fund Advisors held 8 shares of Viridian Therapeutics worth $1K as of Q4 2016.
BlackRock Fund Advisors bought 1 Viridian Therapeutics share in Q4 2016, an estimated $104.
Viridian Therapeutics made up ﹤0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #4202 holding.
BlackRock Fund Advisors first reported a position in Viridian Therapeutics in Q2 2016 and has held it in 3 quarters since.
8 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.